| A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (NCT05378763) | Spectrum Pharmaceuticals, Inc | 2022-05-12 |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (NCT04570423) | Spectrum Pharmaceuticals, Inc | 2021-05-20 |
| A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants (NCT04981704) | Spectrum Pharmaceuticals, Inc | 2021-04-08 |
| A Study of IGN002 for Refractory NHL (NCT02847949) | Spectrum Pharmaceuticals, Inc | 2021-01-01 |
| Study of Poziotinib in Japanese Patients With NSCLC (NCT04402008) | Spectrum Pharmaceuticals, Inc | 2020-06-23 |
| Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects (NCT04436562) | Spectrum Pharmaceuticals, Inc | 2020-05-29 |
| Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer (NCT04187898) | Spectrum Pharmaceuticals, Inc | 2020-03-11 |
| A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies (NCT04172597) | Spectrum Pharmaceuticals, Inc | 2019-12-23 |
| A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib (NCT03804515) | Spectrum Pharmaceuticals, Inc | 2019-06-25 |
| A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib (NCT03744715) | Spectrum Pharmaceuticals, Inc | 2018-10-11 |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer (NCT03429101) | Spectrum Pharmaceuticals, Inc | 2018-07-13 |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (NCT03318939) | Spectrum Pharmaceuticals, Inc | 2017-10-11 |